What does Synergy CHC Corp. do?
Synergy CHC Corp., listed on Nasdaq under SNYR, develops and markets consumer-health products. Its portfolio centers on FOCUSfactor, a brain-health supplement brand, and Flat Tummy, a women-focused wellness brand. The company’s “Brighter & Better Lives” positioning links cognitive wellness, energy, beauty, and lifestyle products. Its official company story emphasizes brand ownership, innovation, and omnichannel distribution.
Which products and customers define the portfolio?
FOCUSfactor spans tablets, gummies, children’s formulations, and beverages. Flat Tummy offers shakes, gummies, teas, supplements, and a fitness application. The official brand portfolio includes non-core assets, but filings concentrate on these two brands. Distribution includes Costco, Amazon, Walmart, Walgreens, BJ’s, and The Vitamin Shoppe.
Why does the asset-light structure matter?
Third-party manufacturing limits factory capital expenditure and supports rapid format expansion. It also creates supplier, quality, lead-time, and working-capital exposure. Synergy is therefore a brand-and-distribution platform whose value depends on consumer demand and retail execution.
How does Synergy CHC make money?
Synergy earns almost all revenue from physical products sold through retailers, distributors, and online channels. Repeat purchases can create recurring behavior, but there is no contractual subscription base. Revenue depends on shelf placement, sell-through, promotions, product acceptance, and retailer reorders.
| Revenue stream | FY2025 revenue | Share of FY2025 revenue | Economic interpretation |
|---|---|---|---|
| Nutraceuticals | $29.73M | 97.9% | Core tablets, gummies, powders, teas, and related wellness products; the dominant revenue base. |
| Beverages | $0.63M | 2.1% | Early-stage FOCUSfactor ready-to-drink expansion with potentially higher frequency but intense competition. |
| Consumer goods | $0.02M | 0.1% rounded | Immaterial non-core sales in FY2025. |
Source period: fiscal year ended December 31, 2025. Percentages are calculated from reported category revenue and may not sum exactly because of rounding.
What is the revenue-to-cash process?
Which economics matter most?
Branded supplements support attractive gross margins, but gross profit must absorb marketing, overhead, and financing. FY2025 gross margin was 67.0% even as the company reported a large operating loss. The key question is whether distribution growth produces operating leverage or requires proportionate spending.
What does Synergy CHC’s latest quarter show?
The Q1 2026 Form 10-Q shows a sharp headline decline because Q1 2025 included $1.50M of license revenue. Product sales also fell, although beverages expanded from a small base.
How did Q1 2026 compare with Q1 2025?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Product sales | $5.49M | $6.67M | Down 17.7%; this removes the license-revenue distortion from the headline comparison. |
| Gross margin | 72.3% | 75.4% | Reported margin declined; the company’s earnings exhibit says margin excluding Q1 2025 license revenue improved versus a 70.0% normalized base. |
| Operating income (loss) | $(0.57)M | $1.95M | Lower sales and higher overhead erased prior-year operating profitability. |
| Interest expense | $2.01M | $1.10M | Q1 2026 interest equaled 36.6% of revenue, making financing cost the largest barrier below operating income. |
| Operating cash flow | $(2.04)M | $(0.82)M | Cash consumption accelerated despite the asset-light operating model. |
What changed in the product mix?
Why are margin and liquidity sending different signals?
How did acquisitions and leverage shape Synergy CHC?
Acquisitions created Synergy’s two core brands, while debt, related-party arrangements, and equity financed the platform. Its strategic history is inseparable from its capital structure.
-
2010
The predecessor was incorporated as Oro Capital Corporation, establishing the public-company shell that later became the consumer-health platform.
-
2014–2015
Management changed the company’s direction and adopted the Synergy CHC name, moving away from the predecessor business.
-
January 2015
Synergy acquired FOCUSfactor for approximately $6.0M including earnout consideration. The brand became the company’s primary revenue engine.
-
November 2015
Synergy acquired Flat Tummy for AUD10.0M, approximately $7.0M at the time, adding a digital-first wellness audience and a second core brand.
-
2020
FOCUSfactor expanded into Canada, proving that the brand could travel beyond the U.S. retail base.
-
2023–2024
Ready-to-drink pilots in Texas and Canada tested a beverage extension before broader distribution, creating a potential second growth engine.
-
2025
Synergy entered Mexico and refinanced legacy obligations with a new term loan. The transaction extended maturity but left the company with expensive leverage.
-
2026
Beverage distribution expanded, while equity facilities and shareholder approvals increased financing flexibility and potential dilution.
What did the 2025 refinancing actually change?
In May 2025, Synergy used new financing to satisfy legacy Knight Therapeutics obligations. An official Form 8-K reported settlement of $12.71M through $10.00M of cash, a $1.21M early-payment discount, and $1.50M converted to equity. The replacement term facility totaled $17.50M, carried a floating rate described as approximately 12.5% at year-end, and matures in May 2029.
What is Synergy CHC’s competitive position in supplements and energy drinks?
Synergy faces low switching costs, crowded shelves, powerful retailers, and heavy marketing. Its advantages are FOCUSfactor’s history, retailer relationships, product breadth, and ability to extend brain health across formats—not patents or a proprietary network.
Where does Synergy have an advantage?
Which competitors define the battleground?
| Competitive arena | Named category references in company filings | Synergy’s position | Main pressure |
|---|---|---|---|
| Brain-health supplements | Numerous branded and private-label supplement companies | FOCUSfactor has longevity and broad retail placement, but no officially disclosed market-share leadership. | Claims differentiation, retailer bargaining power, and paid customer acquisition. |
| Functional energy | Celsius, C4 Smart Energy, FocusAid, Beyond Raw | FOCUSfactor seeks a cognition-plus-energy niche rather than matching the largest brands on scale. | Velocity per store, distributor attention, and promotional spending. |
| Mainstream energy drinks | Red Bull, Monster, Bang, Reign, C4 Performance | A small entrant facing companies with far larger marketing and distribution resources. | Shelf space, brand awareness, and repeat purchase at scale. |
How financially strong is Synergy CHC?
The FY2025 Form 10-K annual report shows healthy gross margins but weak earnings quality, substantial leverage, and limited liquidity. Falling revenue, rising expenses, and receivable write-downs complicate normalization.
What does the FY2025 income statement reveal?
| Metric | FY2025 | FY2024 | Research implication |
|---|---|---|---|
| Revenue | $30.38M | $34.83M | A 12.8% decline, showing that high margin did not come with top-line momentum. |
| Gross profit | $20.30M | $23.64M | Still sizable relative to revenue, but insufficient to cover the expanded cost structure. |
| Selling and marketing | $13.14M | $12.99M | Marketing did not fall with revenue, limiting operating leverage. |
| General and administrative | $8.83M | $4.72M | The near-doubling of overhead was a major deterioration in cost discipline. |
| Bad-debt reserve | $6.66M | $0.00M | A large non-routine charge, including a related-party loan receivable write-off, reduced earnings quality. |
| Net income (loss) | $(12.34)M | $2.12M | The swing reflects both operating deterioration and high financing costs. |
How should the balance sheet be interpreted?
Cash fell from $2.62M at December 31, 2025 to $0.29M at March 31, 2026, while a $1.78M working-capital surplus became a $0.50M deficit. At quarter-end, assets were $6.46M, liabilities were $31.87M, and stockholders’ deficit was $25.41M. Debt service and financing access are therefore central valuation variables.
Who owns SNYR stock, and why does governance matter?
Synergy has one-vote common stock, but ownership is concentrated around Chairman and CEO Jack Ross and controlled entities. The 2026 preliminary proxy statement uses 14.78M shares outstanding on April 24, 2026.
Where is voting influence concentrated?
| Holder or group | Beneficial shares | Ownership at April 24, 2026 | Why it matters |
|---|---|---|---|
| Jack Ross | 4.80M | 32.4% | Combines executive leadership with a large voting block, giving strategy and governance significant founder-like continuity. |
| Gowan Private Equity Inc. | 3.68M | 24.9% | Included in Ross’s beneficial ownership because he controls the entity. |
| Knight Therapeutics International S.A. | 1.91M | 12.9% | A significant strategic holder whose stake reflects the legacy financing relationship. |
| Directors and executive officers as a group | 4.90M | 33.2% | Insider influence is material even though the company does not have a dual-class structure. |
What governance issues deserve attention?
Concentrated ownership can support continuity but raises the importance of independent oversight. The proxy disclosed $0.995M of FY2025 consulting fees to a Ross-owned entity, rent to another controlled entity, and a $4.40M related-party receivable write-off. Transaction approval and recoverability therefore matter to minority holders.
What opportunities could change Synergy CHC’s growth profile?
The main opportunity is turning FOCUSfactor into a broader cognitive-wellness platform. Beverages and new geographies must prove repeatable retail velocity and positive cash contribution after promotions and working capital.
Can beverages become a second engine?
Pilots reported $550–$2,382 per club per week across 44 Texas clubs and C$378–C$2,206 in Canada. The wide ranges make broad-store sell-through more important than initial shipments. Economics must remain viable after distributor margins, freight, promotions, and retailer allowances.
Where could operating leverage appear?
Synergy laid off 13 employees and is targeting liquidity improvement. Stable revenue plus lower overhead could unlock leverage from high gross margin; another marketing step-up could instead prolong cash burn.
What risks could weaken Synergy CHC’s outlook?
Risks reinforce one another: customer concentration drives volatility, volatility pressures cash, and weak cash increases reliance on expensive debt or dilutive equity. Product-quality and regulatory issues could compound those pressures.
Which operating risks are most material?
| Risk | Official evidence | Financial line affected | What to monitor |
|---|---|---|---|
| Customer concentration | Three customers generated 85% of Q1 2026 revenue. | Revenue, receivables, inventory, and promotional allowances. | Top-customer share, reorder timing, and retail sell-through. |
| Supplier concentration | One supplier represented 38% of Q1 2026 purchases. | Gross margin, availability, lead times, and working capital. | Alternative sourcing, quality events, and input-cost changes. |
| Leverage and liquidity | $27.75M of net notes payable and $0.29M cash at March 31, 2026. | Interest expense, covenant headroom, and equity dilution. | Cash burn, debt amendments, ATM usage, and warrant issuance. |
| Receivable quality | $6.66M bad-debt reserve recorded in FY2025. | Operating expense, equity, and reported earnings quality. | Related-party balances, aging, and collection disclosures. |
| Regulatory and claims risk | Products are subject to food, supplement, labeling, and advertising requirements. | Sales, legal expense, recalls, and brand reputation. | Claim language, adverse events, quality controls, and regulator actions. |
Why is dilution a business risk rather than only a stock-market issue?
Equity can preserve liquidity, but Synergy’s share count changed rapidly: 11.30M shares were outstanding at March 31, 2026 versus 14.90M entitled to vote at the April 24 record date. A DCF must therefore use an explicit fully diluted share count rather than a static denominator.
Which KPIs matter most for a Synergy CHC research model?
The best KPIs connect consumer demand to cash. Separate product sales from license items, then test whether gross profit converts to cash after marketing, overhead, and interest.
How should each KPI be interpreted?
What would demonstrate a genuine turnaround?
A genuine turnaround would combine consecutive product-sales growth, beverage gains without core erosion, high-60% or better gross margin, lower overhead, positive operating cash flow, and declining interest. Repeatability matters more than one quarter affected by licensing or working-capital timing.
Why does Synergy CHC’s business model matter for valuation?
A Synergy DCF needs revenue, margin, marketing, overhead, and working-capital assumptions plus explicit debt and diluted-share forecasts. Operating and capital-structure cases must be linked.
| DCF driver | Base analytical question | Upside evidence | Pressure evidence |
|---|---|---|---|
| Revenue growth | Can beverage and international gains exceed core online weakness? | Q1 2026 beverage revenue reached $0.67M. | Q1 2026 product sales declined 17.7%. |
| Operating margin | How much of gross profit survives marketing and overhead? | Q1 2026 gross margin was 72.3%. | Q1 2026 operating margin was negative 10.3%. |
| Reinvestment | How much inventory and promotion are required for each new retailer? | Third-party manufacturing limits fixed-asset needs. | Operating cash flow was negative $2.04M in Q1 2026. |
| Capital structure | How much enterprise value is absorbed by debt and future financing? | The main term maturity extends to May 2029. | Net notes payable were $27.75M at March 31, 2026. |
| Per-share value | What fully diluted share count should divide equity value? | Equity can reduce liquidity pressure. | ATM shares, warrants, options, and approved plan capacity can dilute ownership. |
Which valuation method is most informative?
DCF output is highly sensitive to break-even timing, refinancing, and diluted shares. Comparables are imperfect because larger consumer-health companies usually have stronger balance sheets and steadier cash flow. Sales multiples also ignore whether gross profit converts to cash.
What is the key takeaway from Synergy CHC analysis?
Synergy pairs recognizable wellness brands and high gross margins with a constrained balance sheet. The unresolved issue is converting brand value into stable cash flow and per-share value.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.